Gimsilumab

Last updated
Gimsilumab
Monoclonal antibody
Type ?
Source Human
Target colony stimulating factor 2
Clinical data
Synonyms MORAb-022
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6726H10428N1764O2184S38
Molar mass 152.1 g/mol

Gimsilumab (MORAb-022) (INN [1] ) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.

Rheumatoid arthritis An arthritis that is an autoimmune disease which attacks healthy cells and tissue located in joint.

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.

This drug was developed by Eisai Inc. [2]

References

  1. ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Gimsilumab, American Medical Association.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.